Miller Anestesia

Armas químicas y biológicas: la misión del anestesista

2121

Sección IV

Anestesia por subespecialidades en el adulto

RL, Sidell FR (eds): Chemical Warfare Agents: Toxi-

cology and Treatment, 2nd ed. Chichester, UK, John

Wiley & Sons, 2007, pp 277–286.

4. Hobbiger F: The pharmacology of anticholinesterase

drugs.

In:

Handbook of Experimental Pharmacology

42: The Neuromuscular Junction. Berlin, Springer

Verlag, 1976, pp 487–569.

5. Koelle G (ed): Handbook of Experimental Phar

macology 15: Cholinesterase and Anticholinesterase

Agents. Berlin, Springer Verlag, 1963.

6. White SM: Chemical and biological weapons: Impli-

cations for anaesthetic and intensive care. Br J Anaesth

89:306, 2002.

7. Somani S (ed): Chemical Warfare Agents. San Diego,

Academic Press, 1992.

8. Marrs TC, Maynard RL, Sidell FR (eds): Chemical

Warfare Agents: Toxicology and Treatment, 2nd ed.

Chichester, UK, John Wiley & Sons, 2007.

9. Baker DJ, Rustick JM: Anesthesia for casualties of

chemical warfare agents.

Zaitchuk R, Grande C

(eds): Anesthesia for the Preoperative Care of the

Combat Casualty. Washington, DC, US Department

of the Army, Office of the Surgeon General, Borden

Institute, 1995, pp 833–854.

10. Baker DJ: Anesthesia in extreme environmental con-

ditions, part 2: Chemical and biologic warfare.

Grande CG (ed): Textbook of Trauma Anesthesia and

Critical Care. Baltimore, Mosby Year Book, 1993, pp

1320–1354.

11. Christopher GW, Sieslak TJ, Parlin JA, Eitsen EM:

Biological warfare: A historical perspective. JAMA

278:412, 1997.

12. Franz DR, Jahrburg PB, Friedlander AM, et al: Clinical

recognition and management of patients exposed to

biological warfare agents. JAMA 278:399, 1997.

13. Zaitchuk R, Bellamy RF (eds): Medical Aspects of

Chemical and Biological Warfare Chemical Warfare.

Washington, DC, US Department of the Army, Office

of the Surgeon General, Borden Institute, 1997.

14. Harris R, Paxman J: A Higher Form of Killing.

London, Chatto & Windus, 1982.

15. SIPRI: The Problem of Chemical and Biological

Warfare, Vol 1: The Rise of CBW Weapons. Stoc-

kholm, SIPRI, 1971.

16. Alibek K: Biohazard. London, Arrow Books, 1999.

17. Zilinskas RA: Verifying compliance to the biological

and toxin weapons convention. Crit Rev Microbiol

24:195, 1998.

18. Ministry of Defence: Medical Manual of Defence

Against Chemical Agents, D/Med (F and S)(2)/10/1/1

p1-1. London, Her Majesty’s Stationery Office, 1987.

19. Baker DJ: Chemical and biological warfare agents: A

fresh approach. Jane’s Intelligence Review 5(1): 42–43,

1993.

20. Bronstein AC, Currance PL: Emergency Care for

Hazardous Materials Exposure, 2nd ed. St Louis,

Mosby Lifeline, 1994.

21. Borak J, Callan M, Abbott W: Hazardous Materials

Exposure: Emergency Response and Patient Care.

Upper Saddle River, New Jersey, Prentice Hall, 1991.

22. Gilchrist HL: Statistical consideration of gas casual-

ties.

Weed FW (ed): Medical Aspects of Gas

Warfare, Vol 14, Chapter 8.

Ireland MW (ed): The

Medical Department of the United States Army in the

World War. Washington, DC, Government Printing

Office, 1926.

23. Hemsley J: The Soviet Biochemical Threat to NATO.

London, Royal United Services Institute, Macmillan,

1987.

24. United Nations: Report of the Mission Dispatched by

the Secretary General to Investigate Allegations of the

Use of Chemical Weapons in the Conflict between the

Islamic Republics of Iran and Iraq. UN docu-

ment/18852. New York United Nations, 1987.

25. Hammick M: All stick and no carrot. International

Defense Review 24 Dec 1323, 1991.

26. Tu AT: Overview of the sarin terrorist incidents in

Japan in 1994 and 1995. In: Proceedings of the 6th

BCW Protective Symposium, Stockholm, NDRE.

FOR-R-98, 00949-862-6E, 1998.

27. Okumura T, Suzuki K, Fukada A, et al: The Tokyo

subway Sarin attack: Disaster management, part 2:

Hospital response. Acad Emerg Med 5:618, 1998.

28. Dhara VR, Dhara K: The Union Carbide disaster in

Bhopal: A review of health effects. Arch Environ

Health 57:391–404, 2002.

29. Pita R: Assessing al-Qaeda’s chemical threat. Interna-

tional Journal of Intelligence and Counterintelligence

20:480–511, 2007.

30. Marrs TC: Organophosphates: History, chemistry,

pharmacology. In Laralliedde L, Feldman S, Henry J,

Marrs TC (eds): Organophosphates and Health.

London, Imperial College Press, 2001.

31. Bey T, Deynes S: The differentiated tactical and the-

rapeutical approach to nerve agents of the same che-

mical class as a result of their different physical,

chemical physiological properties [abstract]. Prehosp

Disast Med 22:S153, 2007.

32. Kato T, Hamanaka T: Ocular signs and symptoms

caused by exposure to sarin gas. Am J Ophthalmol

121:209, 1996.

33. Rickett DI, Glenn JF, Beers ET: Central respiratory

effects versus neuromuscular actions of nerve agents.

Neurotoxicology 7:225, 1986.

34. Eddlestone M, Buckley NA, Dawson AH: Manage-

ment of acute organophosphorus pesticide poisoning.

Lancet 371(9612)1597–1607, 2008.

35. Saadeh AM, Farsakh NA, Al-Ali MK: Cardiac mani-

festations of acute carbamate and organophosphate

poisoning. Heart 77:461, 1997.

36. Bar-Meir E, Schein O, Eisenkraft A, et al: Guidelines

for treating cardiac manifestations of organophospha-

tes poisoning with special emphasis on long QT and

torsades de pointes. Crit Rev Toxicol 37:279–285,

2007.

37. Kadivar H, Adams SC: Treatment of chemical and

biological warfare injuries: Insights gained from the

1984 Iraqi attack on Majnoon Island. Milit Med

156:171, 1991.

38. Murray V, Minton NA: A review of organophosphate

poisoning. Med Toxicol Adverse Drug Exp 3:350, 1988.

39. Ram JS, Kumar SS, Kuppuswamy G: Continuous

infusion of high doses of atropine in the manage-

ment of organophosphorus compound poisoning.

J Assoc Phys Ind 39:190, 1991.

40. Marrs T, Rice P, Vale A: The role of oximes in the

treatment of nerve agent poisoning in civilian casual-

ties. Toxicol Rev 25:297–323, 2006.

41. Worek F, Backer M, Thiermann H, et al: Reappraisal

of indications and limitations of oxime therapy in

organophosphate poisoning. Hum Exp Toxicol

16:466, 1997.

42. Inns RH, Leadbeater L: The efficacy of bispyridinium

compounds in the treatment of organophosphate poi-

soning in the guinea pig. J Pharm Pharmacol 5:427,

1983.

43. Worek F, Eyer P, Kiderlen D, et al: Effect of human

plasma on the reactivation of sarin-inhibited human

erythrocyte acetylcholinesterase. Arch Toxicol 74:21,

2000.

44. Holstege CP, Kirk M, Sidell FR: Chemical warfare:

Nerve agent poisoning. Crit Care Clin 13:923, 1997.

45. McDonough JH Jr, Zoeffel LD, McMonagle J, et al:

Anticonvulsant treatment of nerve agent seizures:

Anticholinergics versus diazepam in soman-intoxica-

ted guinea pigs. Epilep Res 38:1, 2000.

46. Keeler JR, Hurst CG, Dunn MA: Pyridostigmine used

as a nerve agent pretreatment under wartime condi-

tions. JAMA 266:694, 1991.

47. Pellegrini JE, Baker AB, Fontenot DJ, Cardenas AF:

The effect of oral pyridostigmine bromide nerve

agent prophylaxis on return of twitch height in

persons receiving succinyl choline. Milit Med

165:252, 2000.

48. Turner GA, Williams JD, Baker DJ: Effect of pre-

treatment with oral pyridostigmine on subsequent

activity of alcuronium in non-anaesthetized subjects.

Br J Anaesth 66:365, 1991.

49. Ali HH, Savarese JJ: Monitoring of neuromuscular

function. Anesthesiology 45:216, 1975.

50. Bowman WC: Prejunctional and postjunctional cho-

linoceptors at the neuromuscular junction. Anesth

Analg 59:935, 1980.

51. Sidell FR, Hurst CG: Clinical considerations in

mustard poisoning. In Somani S (ed): Chemical

Warfare Agents. San Diego, Academic Press, 1992.

52. Willems JL: Clinical management of mustard gas

casualties. Ann Med Milit Belg 3(Suppl): 1, 1989.

53. Balali Mood M: Clinical and laboratory findings in

Iranian fighters with chemical gas poisoning. Arch

Belg(Suppl): 254–259, 1984.

54. Urbanetti JS: Toxic inhalation injury. In Zajchuk R

(ed): Textbook of Military Medicine, part 1, vol 5:

Medical Aspects of Chemical and Biological Warfare.

Washington, U.S. Department of the Army, 1997.

55. Borak MD, Sidell F: Agents of chemical warfare:

Sulfur mustard. Ann Emerg Med 21:308, 1992.

56. Colardyn F, de Keyser H, Ringoir S, de Bersaques

J: Clinical observations and therapy of injuries with

vesicants. J Toxicol Clin Exp 6:237, 1986.

57. Varma DR, Guest I: The Bhopal incident and methyl iso-

cyanate toxicity. J Toxicol Environ Health 40:513, 1993.

58. Mehta PS, Mehta AS, Mehta SJ, Makhijani AB: Bhopal

tragedy’s health effects: A review of methyl isocyanate

toxicity. JAMA 264:2781, 1990.

59. Maynard R: Phosgene.

Marrs TC, Maynard RL,

Sidell FR (eds): Chemical Warfare Agents: Toxicology

and Treatment, 2nd ed. Chichester, UK, John Wiley &

Sons, 2007.

60. Diller WF: Medical phosgene problems and their pos-

sible solution. Occup Med 20:189, 1978.

61. Papadakos P, Lachmann B: The open lung concept of

alveolar recruitment can improve outcome in respiratory

failure and ARDS. Mt Sinai J Med 69(1-2): 73, 2002.

62. Lachman B: The concept of open lung management.

Int J Intensive Care 7:215, 2000.

63. Parkhouse DA, Brown RF, Jugg BJ, et al: Protective

ventilation strategies in the management of phos-

gene-induced acute lung injury. Milit Med 172:295–

300, 2007.

64. Diller WF: Therapeutic strategy in phosgene poiso-

ning. Toxicol Ind Health 1:93, 1985.

65. Gunnarsson M, Walther SM, Seidal T, Lennquist S:

Effects of inhalation of corticosteroids immediately

after experimental chlorine gas lung injury. J Trauma

48:101, 2000.

66. Wang J, Zhang L, Walther SM: Inhaled budesonide in

experimental chlorine gas chlorine gas injury:

Influence of time interval between injury and

treatment. Intensive Care Med 28:352, 2002.

67. Demnati R, Fraser R, Martin JG, et al: Effects of dexa-

methasone on functional and pathological changes in

rat bronchi caused by high acute exposure to chlorine.

Toxicol Sci 45:242, 1998.

68. Borak J, Diller WF: Phosgene exposure: Mechanisms

of injury and treatment strategies. J Occup Environ

Med 43:110–119, 2001.

69. Kennedy TP, Michael JR, Hoidal JR, et al: Dibutaryl

cAMP, aminophylline and beta-adrenergic agonists

protect against pulmonary oedema caused by phos-

gene. J Appl Physiol 67:2542, 1989.

70. Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH:

Protective effects of N-acetyl cysteine treatment after

phosgene exposure in rabbits. Am J Respir Crit Care

Med 151:768, 1995.

71. Baskin SI, Brewer TG: Cyanide poisoning. In Zaichuk

R (ed): Textbook of Military Medicine and Biological

Warfare. Washington, DC, U.S. Department of the

Army, 1997, p 271.

72. Meredith TJ, Jacobsen D, Haines JA, et al (eds): IPCS/

CEC Evaluation of Antidote Series, vol 2: Antidotes

for Poisoning by Cyanide. Cambridge, UK, Cam-

bridge University Press, 1993.

73. Beasley DMG, Glass WI: Cyanide poisoning: Patho-

physiology and treatment recommendations. Occup

Med 48:427, 1998.

74. Baskin SI, Horowitz AM, Nealley EW: The antidotal

action of sodiumnitrite and sodium thiosulfate against

cyanide poisoning. J Clin Pharmacol 32:368, 1992.

75. Way JL: Cyanide intoxication and its mechanism of

antagonism. Ann Rev Pharmacol Toxicol 24:451–481,

1984.

76. Karalliedde L: Animal toxins. Br J Anaesth 74:319,

1995.

77. Franz DR: Defense against toxin weapons. In Zait-

chuk R, Bellamy RF (eds): Medical Aspects of Chemi-

cal and Biological Warfare. Washington, DC, US

Department of the Army, Office of the Surgeon

General, Borden Institute, 1997, pp 603–619.